Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
M7824 (bintrafusp alfa) plus paclitaxel in recurrent/metastatic gastric cancer (second-line)
KCT0006078Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Jun 2021
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of bintrafusp alfa, paclitaxel in gastric cancer (GC), sponsored by Merck & Co.. Started Jun 2021; status: completed.
02
Drugs
bintrafusp alfapaclitaxel
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on KCT0006078.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0006078.